Introduction
============

One major concern in management of schizophrenia is sleeping domain. Because sleep difficulty is commonly reported in around 30%--80% of schizophrenia patients, and might due to the disease itself and from the effect of antipsychotic medication, reduction in quality of sleep might worsen daily activity function and reduce patients' quality of life.[@b1-prbm-10-323] In schizophrenia patients, their sleep pattern compared to healthy population is significantly different including the variation in sleep latency and density, which has various stages such as stage two sleep, slow-wave sleep, and rapid eye movement (REM).

First-generation antipsychotics show inconsistent effects in measures of sleep continuity and structure. Treatment of schizophrenia with first-generation antipsychotics might be associated with increases in total sleep time, sleep efficiency, and, primarily, an increase in REM latency; however, the influence on specific sleep stages is more variable. Accordingly, withdrawal of such treatment is followed by a change in sleep structure mainly in the opposite direction, with a deterioration of sleep quality. Also, there are studies suggesting that first-generation antipsychotics have shown rather inconsistent effects on sleep in healthy subjects, but seem to exert effects indirectly on sleep in patients with schizophrenia on high-potency drugs, and this is by suppressing stressful psychotic symptoms.[@b2-prbm-10-323]

In contrast, the available data regarding the use of second-generation antipsychotics (clozapine, olanzapine, risperidone, and paliperidone) demonstrate a relatively consistent effect on measures of sleep continuity in patients and in healthy subjects, with an increase in total sleep time and sleep efficiency, which results in improvement of sleep quality. Additionally, clozapine and olanzapine demonstrate comparable influences on other sleep variables, such as slow-wave sleep or REM density, in controls and schizophrenic patients.[@b3-prbm-10-323]

Paliperidone extended-release (paliperidone ER) formulation is recommended for use as once-daily dosing for the treatment of schizophrenia patients. Paliperidone ER has shown efficacy and safety data at the recommended dose between 3 and 12 mg per day in three clinical studies. The results from these studies suggest that paliperidone significantly improves personal and social function scores compared to placebo, which might be due to the improvement of sleep function.[@b4-prbm-10-323]--[@b6-prbm-10-323] The efficacy data of paliperidone in schizophrenia symptom control is established in both acute and maintenance setting.[@b7-prbm-10-323],[@b8-prbm-10-323] For the sleeping domain, available evidence suggests that paliperidone ER might increase the sleep quality and reduce daytime drowsiness.[@b9-prbm-10-323] However, there is still limited evidence to prove the effect of paliperidone ER on sleeping domain, and especially the available data are very scarce in Asian population. Therefore, the main objective of this study was to evaluate the sleep profiles after the use of paliperidone ER in Southeast Asian patients with schizophrenia.

Methods
=======

Population
----------

The study was conducted during June 2007 to April 2009. We recruited 984 patients with schizophrenia from five countries in Southeast Asia (Thailand, Singapore, Malaysia, Hong Kong, and the Philippines). The diagnosis of schizophrenia was based on *The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (DSM-IV) criteria. Our focus population includes patients who have had previously unsuccessful treatment with oral atypical antipsychotic medication, either because of unsatisfactory efficacy or tolerability, or due to other reasons such as lack of compliance or loss to follow-up. Inclusion criteria also included age (at least 18 years old), provision of signed informed consent, and good physical health based on vital screening and baseline physical examination. Exclusion criteria included patients who had received other long-acting antipsychotics during the 3 months preceding the study or those with known hypersensitivity to risperidone or paliperidone. This study was reviewed and approved by the responsible ethics committee within each country\*.

\*Ethics committees in each country are as follows: Hong Kong: Institutional Review Board of the University of Hong KongMalaysia: Medical Research and Ethics Committee Ministry of Health Malaysia and University Malaya Medical Centre Medical Ethics CommitteePhilippines: St. Luke's Institutional Ethics Review BoardSingapore: Parkway Independent Ethics Committee, National Healthcare Group Domain Specific Review Board and Singapore General Hospital Institutional Review BoardThailand: Joint Research Ethics Committees, Bangkok, Thailand

Assessment
----------

Patients enrolled in the study received paliperidone ER for 6 months. Throughout the study, flexible dosing of 3--12 mg per day was given, depending on efficacy and tolerability. Assessments of efficacy and safety were carried out at baseline and throughout the study period. To examine efficacy, we used Positive and Negative Syndrome Scale (PANSS; total and subscale scores) and Clinical Global Impression severity score, personal and social performance scale, and patient satisfaction score. For tolerability, safety assessments were monitored throughout the 6-month study period and comprised adverse events reporting, pregnancy testing, extrapyramidal symptom scoring, physical examination, and vital signs. Concomitant medication including the use of benzodiazepines and other sleeping pills was recorded throughout the study period. Missing data were handled using the last-observation-carried-forward method.

For assessment of the drug's effects on sleep, we used patient-completed visual analog scales of sleep quality and daytime drowsiness, scored from 0 to 100 (higher scores indicating better sleep quality in sleep quality scale and higher score indicating more daytime drowsiness in daytime drowsiness scale). We collected these data at three periods of the study: baseline, after 1 month of treatment, and at the end of the study.

Statistical analysis
--------------------

All subjects who received paliperidone ER at least once were included in the analysis. Descriptive statistics were used to analyze demographic data and baseline characteristics. For sleep profile (sleep quality and daytime drowsiness scales), we used paired *t*-tests to compare sleeping score at the end of study period to baseline. We also performed regression analysis using the Enter method to evaluate the important factors associated with sleep profile. Statistical tests for differences between the endpoint and baseline values were interpreted at the 5% significance level (two-tailed) without multiplicity adjustment.

Results
=======

We recruited 984 patients with schizophrenia, with a mean age of 36.2 years. Of these, 70% completed the full 6 months of paliperidone ER treatment as specified in the study protocol. Patient characteristics including gender and baseline scores are summarized in [Table 1](#t1-prbm-10-323){ref-type="table"}.

Compared with baseline, patients receiving paliperidone treatment showed significant improvements in their sleep quality (76.44 vs 65.48; *p*\<0.001; [Table 2](#t2-prbm-10-323){ref-type="table"}) and a significant reduction in daytime drowsiness (23.18 vs 34.22; *p*\<0.001).

We also conducted linear regression analysis to explore factors associated with sleep quality. Multivariate analysis indicated that mean baseline PANSS score and completion of the study are the important predictive factors for improvement of sleep quality ([Table 3](#t3-prbm-10-323){ref-type="table"}).

The daytime drowsiness scale showed a similar (inverse) pattern to the sleep quality scale, with multivariate analysis indicating that mean baseline PANSS score and completion of the study predict reductions in daytime drowsiness ([Table 4](#t4-prbm-10-323){ref-type="table"}).

Discussion
==========

The present study demonstrates that paliperidone ER improves sleep profile in people with schizophrenia. Patients receiving paliperidone ER showed improvements in sleep quality and daytime drowsiness compared to baseline values (before the switch to paliperidone ER).

Our results are consistent with those of Luthringer et al,[@b9-prbm-10-323] which suggested that paliperidone ER has a positive effect on sleep architecture, continuity, and patient-rated sleep quality, without producing or worsening daytime sleepiness. Therefore, the improvement of schizophrenia symptoms by this antipsychotic might be associated with improvements in sleep quality and a resulting decrease in daytime drowsiness.

The effect of paliperidone on sleep might reflect its pharmacodynamics. Paliperidone ER has a very high affinity for serotonin and dopamine receptors, which underlies its efficacy in the treatment of schizophrenia. Conversely, it has very little effect on muscarinic acetylcholine receptors, which might be the reason for the lower rates of sleep disturbance observed with paliperidone ER compared with other anti-psychotics with a high affinity for cholinergic receptors.[@b10-prbm-10-323]

People who have higher PANSS scores at baseline seem to have a better quality of sleep and greater reduction of daytime drowsiness after treatment with paliperidone ER. This finding is consistent with previous results that showed that schizophrenia patients with higher PANSS scores have a greater response to antipsychotics than those with lower PANSS scores.[@b11-prbm-10-323]

Another observation from the present study was that patients within the completion group had significantly better quality of sleep, which reflects the association between compliance in taking antipsychotic medication and schizophrenia treatment outcomes.[@b12-prbm-10-323] Together, these results highlight the importance of improving patient compliance in the overall outcome of schizophrenia treatment, including sleep profile.

Our study has some limitations. As we used subjective measures of sleep quality and daytime drowsiness, ie, patients' self-administered questionnaires, this might lead to reporting bias that can reduce the validity and the reliability of the study result. Further studies using objective outcomes including sleeping indicated parameters or sleeping architecture graph might give a more validated result. Also, as the concomitant medication and concomitant disease might have confounding effects on the result, the results might need to be adjusted. However, we could not measure and evaluate the effect of concomitant medication and concomitant disease in this study.

A recent systematic review and meta-analysis revealed that patients with schizophrenia have a greater degree of sleep dysfunction than healthy subjects.[@b13-prbm-10-323] Therefore, medications that improve sleep could be beneficial for patients with schizophrenia.

Conclusion
==========

Paliperidone ER can help schizophrenia patients to improve sleep quality and reduce daytime drowsiness, and this was seen especially in the patients who completed the 6-month treatment period and had higher baseline PANSS score.
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###### 

Baseline characteristics of patients

  Demographic data                 Number
  -------------------------------- ---------------
  Number of patients               984
  Mean age (SD), years             36.2 (11.52)
  Gender                           
   Male (N) (%)                    563 (57.2%)
   Female (N) (%)                  421 (42.8%)
  Mean baseline PANSS score (SD)   74.37 (29.85)
  Mean baseline ESRS score (SD)    23.58 (15.40)
  Mean baseline CGI-S score (SD)   3.72 (1.14)
  Mean baseline PSP score (SD)     31.03 (17.13)
  Completion of the study          
   Complete, N (%)                 700 (71.1)
   Discontinuation, N (%)          284 (28.9)

**Notes:** Statistical analysis using descriptive analysis including mean, SD, and percentage.

**Abbreviations:** CGI-S, Clinical Global Impression -- Severity; ESRS, Extrapyrimidal Symptom; PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Social Performance.

###### 

Sleep profile

  Scale, mean (SD)     Baseline        Month 1         End of the study   *p*-value (baseline vs end of the study)
  -------------------- --------------- --------------- ------------------ ------------------------------------------
  Sleep quality        65.48 (27.65)   72.88 (25.19)   76.44 (26.01)      \<0.001
  Daytime drowsiness   34.22 (28.43)   26.01 (25.07)   23.18 (25.70)      \<0.001

**Notes:** Statistical analysis using paired *t*-test.

###### 

Linear regression model for sleep quality

  Factors                     Univariate analysis (B, *p*-value)   Multivariate analysis (B, *p*-value) (Enter method)
  --------------------------- ------------------------------------ -----------------------------------------------------
  Age                         --0.160 (0.031)                      --0.124 (0.068)
  Gender (male)               --3.422 (0.047)                      --1.439 (0.363)
  Mean Baseline PANSS score   0.132 (\<0.001)                      0.174 (\<0.001)
  Mean Baseline ESRS score    0.053 (0.335)                        N/A
  Mean Baseline CGI-S score   2.072 (0.005)                        --0.661 (0.531)
  Mean Baseline PSP score     --0.112 (0.024)                      0.044 (0.514)
  Completion of the study     23.44 (\<0.001)                      21.623 (\< 0.001)

**Notes:** Statistical analysis using Linear Regression Model.

**Abbreviations:** CGI-S, Clinical Global Impression -- Severity; ESRS, Extrapyrimidal Symptom; N/A, not applicable; PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Social Performance.

###### 

Linear regression model for daytime drowsiness

  Factors                     Univariate analysis (B, *p*-value)   Multivariate analysis (B, *p*-value) (Enter method)
  --------------------------- ------------------------------------ -----------------------------------------------------
  Age                         0.055 (0.449)                        N/A
  Gender (male)               1.797 (0.291)                        N/A
  Mean baseline PANSS score   --0.146 (\<0.001)                    --0.191 (\<0.001)
  Mean baseline ESRS score    0.004 (0.946)                        N/A
  Mean baseline CGI-S Score   --1.841 (0.012)                      1.194 (0.274)
  Mean baseline PSP Score     0.106 (0.030)                        --0.074 (0.280)
  Completion of the study     --13.307 (\<0.001)                   --11.447 (\<0.001)

**Notes:** Statistical analysis using linear regression model.

**Abbreviations:** CGI-S, Clinical Global Impression -- Severity; ESRS, Extrapyrimidal Symptom; N/A, not applicable; PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Social Performance.
